In a 12-week pilot, people with early Huntington’s who confined eating to a daily window showed improvements in disease and nerve-damage markers — but with no control group, the researchers stress it’s far from proof.
Interim results from a randomized trial suggest that halving the length of antibiotic treatment for surgically treated orthopedic infections doesn’t worsen outcomes — and causes fewer side effects.
IUD placement can hurt — and patients have long said so. A double-blind randomized trial found a lidocaine paracervical block reduced pain, especially for those who’ve never given birth.
Brenipatide belongs to the same class as tirzepatide — but it’s tuned for the brain. Early data have Lilly moving it straight into late-stage trials for alcohol use disorder and depression.
The faith’s governing body will now permit members to accept the major blood components and blood-derived products, while maintaining its prohibition on whole-blood transfusions.
Ultragenyx priced Fayuvi, its just-approved gene therapy for a fatal childhood disease, at $3.95 million — reigniting the hard question of how society pays for one-time treatments that carry blockbuster price tags but treat only a handful of patients.
Removing the fallopian tubes during another planned surgery can sharply cut the risk of the deadliest ovarian cancer. The evidence is strong; the challenge is making sure eligible people are actually offered it.
Among people who had both an irregular heartbeat and Alzheimer’s, those on newer anticoagulants declined slightly more slowly — a hint that protecting the brain’s blood supply may help, though the study can’t prove cause.
Some cells begin the self-destruct process, then abort it and go on to rebuild damaged tissue. The finding reveals a hidden engine of regeneration — and a possible clue to why some cancers come back stronger.
A major review confirms that exercise-based cardiac rehabilitation delivers lasting benefits after heart disease. The bigger problem, a companion review finds, is that most eligible patients never take part.
Wernicke encephalopathy, caused by a lack of vitamin B1, can be reversed if caught early — but doctors frequently miss it because the “classic” warning signs usually don’t all show up.
By disabling the antioxidant shield that tumor cells use to survive, the experimental drug RSO-021 lets a cancer’s own toxic byproducts build up until it destroys itself — with promising early results in a hard-to-treat disease.